Multi-Company Product Listing Agreements On The Rise In Canada
Executive Summary
The pan-Canadian Pharmaceutical Alliance has negotiated product listing agreements with three hepatitis C drug makers in one of its first major negotiations with multiple manufacturers. The pCPA may want to negotiate more deals with several companies at once, particularly those with drugs in crowded markets.
You may also be interested in...
Canada Considers Performance-Based Outcome Reimbursement Deals For Oncology Drugs
Manufacturers selling oncology drugs in Canada could soon face group price negotiations and performance-based reimbursement agreements as authorities in the country plan to improve access to oncology drugs.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.